کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8466436 | 1549494 | 2016 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer.
ترجمه فارسی عنوان
نور و طرف های تاریک اینترلوکین 10 در بیماری های ایمنی و سرطان.
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
بیولوژی سلول
چکیده انگلیسی
Interleukin-10 (IL-10) is known to be a tolerogenic cytokine since it inhibits pro-inflammatory cytokine production and T cell stimulatory capacities of myeloid cells, such as macrophages and dendritic cells. In particular, it has a non-redundant tolerogenic role in intestinal immune homeostasis, since mice and patients with genetic defects in the IL-10/IL-10R pathway develop spontaneously colitis in the presence of a normal intestinal flora. However, IL-10 is also a growth and differentiation factor for B-cells, can promote autoantibody production and has consequently a pathogenic role in systemic lupus erythematosus. Moreover, IL-10 can promote cytotoxic T-cell (CTL) responses and this immunogenic activity might be relevant in type-1 diabetes and anti-tumor immune responses. This review summarizes these paradoxic effects of IL-10 on different types of immune responses, and proposes that different cellular sources of IL-10, in particular IL-10-secreting helper and regulatory T-cells, have different effects on B-cell and CTL responses. Based on this concept we discuss the rationales for targeting the IL-10 pathway in immune-mediated diseases and cancer.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Cytokine & Growth Factor Reviews - Volume 30, August 2016, Pages 87-93
Journal: Cytokine & Growth Factor Reviews - Volume 30, August 2016, Pages 87-93
نویسندگان
Jens Geginat, Paola Larghi, Moira Paroni, Giulia Nizzoli, Alessandra Penatti, Massimiliano Pagani, Nicola Gagliani, Pierluigi Meroni, Sergio Abrignani, Richard A. Flavell,